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Text: 440 words 
Figure legend: 165 words  
A 37 year-old woman was referred to our clinic with difficult-to-control hypertension 
since age 12 years.  At 18 years, enalapril was administered. One year before referral to our 
department, she was admitted with a left-sided hemiparesis and pressure values >200/120 mm 
Hg. Thereafter, blood pressure lowering treatment was intensified and a statin was begun. The 
patient is a short-statured ballet dancer (her height is 143 cm). Physical examination was 
otherwise devoid of target-organ damage. There was no evidence of left ventricular 
hypertrophy. Laboratory tests including electrolytes, acid-base balance, and renal function 
were normal. Both her brother and mother also had hypertension at a young age. A plain 
roentgenogram of her hand was revealing (Figure 1). 
What is your diagnosis? 
 
 
 
 
 
 
 
  
The diagnosis: HTNB (OMIM 112410) 
The patient has a Mendelian form of hypertension, autosomal-dominant hypertension 
with type E brachydactyly (HTNB). The family was aware of the diagnosis from the OMIM 
(112410) database (figure 2A). HTNB is a non-salt sensitive form of hypertension featuring a 
remarkable increase in blood pressure with increasing age amounting to about 50 mm Hg by 
age 50 years.1 Untreated, HTNB results in stroke before age 50 years. Heart failure and renal 
failure are not common.  
Gain-of-function mutations in the gene encoding phosphodiesterase 3A (PDE3A) were 
recently shown to cause HTNB.1 The mutated enzyme has an enhanced cAMP-hydrolytic 
activity due to increased phosphorylation of two serines at positions 428 and 438 in close 
proximity to the mutations. We screened the highly conserved area in exon 4 of PDE3A and 
found that our affected family members had a mutation at glycine 449 (figure 2A). A 
Canadian family had a valine substitution at this point (figure 2B), whereas our family here 
has a novel aspartic acid substitution at this same site (p.G449D). To prove that this novel 
mutation also causes hyperphosphorylation we relied on a peptide SPOT assay of the PDE3A 
Gly449Asp mutant. Compared to wildtype peptide the mutation leads to a significantly 
enhanced phosphorylation at the PDE3A Ser438 residue, as we showed earlier (figure 2C and 
2D).1  
HTNB was initially described in a Turkish kindred; phenotyping showed that the 
hypertension resembles essential hypertension, as opposed to all other Mendelian 
hypertensive syndromes described to date that feature increased sodium reabsorption in the 
distal nephron. Blood pressure lowering generally requires 2-3 different drug classes to avoid 
premature stroke, as underscored by our patient. Other target organs such as eye, kidney, 
coronaries, and heart are less affected.2 Neurovascular contact at the rostral ventrolateral 
medulla and faulty baroreceptor reflex regulation are also described. Renin-angiotensin-
catecholamine values, acid-base regulation, and responses to provocative manoeuvres are 
normal in HTNB.2 
We believe that the HTNB findings are relevant to essential hypertension. First, a 
linkage analysis led to this locus in Chinese families with essential hypertension without a 
skeletal phenotype.1,2 Second, two separate genome-wide association studies have identified 
PDE3A in cohorts with essential hypertension.2,3 Third, the PDE3 inhibitor milrinone lowers 
blood pressure both systemically and in the pulmonary circulation. More modest PDE3A 
variation could contribute to essential hypertension. The enzyme is an attractive drug target 
since it is inhibited by increasing cyclic GMP and could also be addressed by specific protein-
protein interactions functioning at intracellular microdomains.2 Physicians treating 
hypertension should be familiar with this syndrome. 
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 Figure 1. Shortened metacarpals and cone-shaped epiphyses feature brachydactyly type E. 
Figure 2. HTNB in a Dutch kindred. 
(A) The family tree shows the affected mother and two offspring, including our patient. We 
identified a novel missense mutation (c.1346 G>A; NM_000921) in PDE3A resulting in a 
glycine for aspartic acid substitution at protein position 449. (B) The sites of mutations we 
have identified to date are given, as is the conserved nature of the protein. (C) We performed 
Phosphokinase A (PKA) phosphorylation of SPOT-synthesized peptides. The principle is 
based on comparing the signal intensity of different peptide sequences after in-vitro 
phosphorylation with PKA catalytic subunit at the corresponding phosphosite S438. Without 
incubation of PKA catalytic subunit only spotted phosphoserine at position 438 can be 
detected by PKA phosphosubstrate antibody. A phosphoserine substitution at S428 and an 
alanine substitution at both S428 and S438 confirmed the specificity of the antibody. Upon 
incubation with PKA catalytic subunit spotted serine at position 438 was phosphorylated (WT 
and G449D sequence). (D) Densitometric quanitification of chemoluminescence signals 
reveal a significantly increased phosphorylation of S438 of the G449D mutation (mean ± 
s.e.m.; biological replicates, n = 26; two-tailed students t-test, ***P < 0.001). 
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